Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte d...

Descripción completa

Detalles Bibliográficos
Autores principales: Popelová, O, Štěrba, M, Hašková, P, Šimůnek, T, Hroch, M, Gunčová, I, Nachtigal, P, Adamcová, M, Geršl, V, Mazurová, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/
https://www.ncbi.nlm.nih.gov/pubmed/19623174
http://dx.doi.org/10.1038/sj.bjc.6605192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/
https://www.ncbi.nlm.nih.gov/pubmed/19623174
http://dx.doi.org/10.1038/sj.bjc.6605192

Ejemplares similares